A Phase 3 interventional study of Rapid-Acting Intramuscular Olanzapine and Placebo in Schizophrenia, sponsored by Eli Lilly and Company. Completed at 11 sites in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2012-03-07.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.
Among the 97 studies testing olanzapine in Schizophrenia, this one is the 57th largest by enrollment of the 94 interventional ones that give a count, is one of 3 that started in 2009, is one of 25 in phase 3, and was the 62nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 25 · Phase 4 46
First in 1997; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 94 interventional studies. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 97 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
33 studies in Schizophrenia by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 31 finished, 9 (29%) have results posted.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 24th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2009, is one of 10 in phase 3, and was the 30th registered.
Eli Lilly and Company’s Schizophrenia studies by the year they started, since 2001.
2 of the studies testing olanzapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies testing olanzapine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 33 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than intramuscular placebo by comparing changes from baseline to 2 hours after the first IM injection of agitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rapid-Acting Intramuscular Olanzapine
Drug: Placebo
Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
Also known as: LY170053, RAIM
Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection
Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.
Time frame: Baseline, up to 2 hours after first IM injection
Change From Baseline in PANSS-EC Total Score up to 90 Minutes After the First Intramuscular (IM) Injection
Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.
Time frame: Baseline, 15 minutes, 30 minutes, 60 minutes, and 90 minutes after the first injection
Change From Baseline in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 24 Hours After the First Intramuscular (IM) Injection
Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.
Time frame: Baseline, up to 24 hours after first IM injection
Percentage of Participants With 40% or Greater Percent Decrease in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection
Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.
Time frame: Up to 2 hours after the first (IM) injection
Percentage of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) Score up to 24 Hours After the First Intramuscular (IM) Injection
The ACES differentiates agitation, calmness, and sleep-state, using a 9-point scale: 1 (Marked Agitation) to 9 (Unarousable). Scores of 4 (Normal) to 7 (Marked Calmness) were used for this outcome measure.
Time frame: up to 24 hours after the first IM injection
Percentage of Participants With Treatment-Emergent Extrapyramidal Symptoms Based on the Drug Induced Extrapyramidal Symptoms Scale (DIEPSS) Score up to 24 Hours After the First Intramuscular (IM) Injection
Assesses extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms; 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). Total points of 8 items are defined as DIEPSS total (0 to 32 points). Items for assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Parkinsonism is assessed by total points of items 1 to 5; akathisia, dystonia and dyskinesia are assessed by points given to corresponding items (item 6, item 7, and item 8, respectively).
Time frame: Up to 24 hours after the first IM injection
| Milestone | 10 mg Olanzapine | Placebo |
|---|---|---|
| Started | 46 | 45 |
| Full analysis set | 45 | 45 |
| Completed | 44 | 29 |
| Not completed | 2 | 16 |
| Withdrew: Lack of efficacy | 1 | 14 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 |
Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.
| units on a scale | 10 mg Olanzapine | Placebo |
|---|---|---|
| Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection | -9.2 ± 4.5 | -2.8 ± 5.6 |
Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.
| units on a scale | 10 mg Olanzapine | Placebo |
|---|---|---|
| 0.25 hour after First IM Injection | -2.4 ± 2.9 | -1.0 ± 3.1 |
| 0.50 hour after First IM Injection | -5.0 ± 3.6 | -1.9 ± 4.6 |
| 1 hour after First IM Injection | -7.3 ± 4.9 | -3.0 ± 5.2 |
| 1.5 hour after First IM Injection | -8.2 ± 4.7 | -2.7 ± 5.0 |
Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.
| units on a scale | 10 mg Olanzapine | Placebo |
|---|---|---|
| Change From Baseline in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 24 Hours After the First Intramuscular (IM) Injection | -5.6 ± 5.8 | -2.8 ± 6.4 |
Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.
| percentage of participants | 10 mg Olanzapine | Placebo |
|---|---|---|
| Percentage of Participants With 40% or Greater Percent Decrease in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection | 40.0 | 13.6 |
The ACES differentiates agitation, calmness, and sleep-state, using a 9-point scale: 1 (Marked Agitation) to 9 (Unarousable). Scores of 4 (Normal) to 7 (Marked Calmness) were used for this outcome measure.
| percentage of participants | 10 mg Olanzapine | Placebo |
|---|---|---|
| 0.5 hour after First IM Injection | 24.4 | 11.4 |
| 1 hour after First IM Injection | 31.1 | 15.9 |
| 1.5 hours after First IM Injection | 40.0 | 13.6 |
| 2 hours after First IM Injection | 40.0 | 13.6 |
| 24 hours after First IM Injection | 28.9 | 15.9 |
Assesses extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms; 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). Total points of 8 items are defined as DIEPSS total (0 to 32 points). Items for assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Parkinsonism is assessed by total points of items 1 to 5; akathisia, dystonia and dyskinesia are assessed by points given to corresponding items (item 6, item 7, and item 8, respectively).
| percentage of participants | 10 mg Olanzapine | Placebo |
|---|---|---|
| Parkinsonism (N=43, 44) | 4.7 | 6.8 |
| Akathisia (N=43, 45) | 0.0 | 0.0 |
| Dystonia (N=44, 45) | 0.0 | 0.0 |
| Dyskinesia (N=44, 45) | 0.0 | 0.0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg Olanzapine | — | 0/45 (0%) | 13/45 (28.9%) |
| Placebo | — | 0/45 (0%) | 6/45 (13.3%) |
| Event | 10 mg Olanzapine | Placebo |
|---|---|---|
| SomnolenceNervous system disorders | 7/45 | 2/45 |
| Blood urine presentInvestigations | 0/45 | 2/45 |
| BradycardiaCardiac disorders | 0/45 | 1/45 |
| ConstipationGastrointestinal disorders | 1/45 | 0/45 |
| HaemorrhoidsGastrointestinal disorders | 1/45 | 0/45 |
| Mouth haemorrhageGastrointestinal disorders | 0/45 | 1/45 |
| NauseaGastrointestinal disorders | 1/45 | 0/45 |
| FatigueGeneral disorders | 0/45 | 1/45 |
| MalaiseGeneral disorders | 1/45 | 1/45 |
| PyrexiaGeneral disorders | 1/45 | 1/45 |
| Age Continuous(years) | 10 mg Olanzapine | Placebo | Total |
|---|---|---|---|
| Mean | 46.4 ± 11.7 | 47.0 ± 12.1 | 46.7 ± 11.9 |
| Sex: Female, Male(Participants) | 10 mg Olanzapine | Placebo | Total |
|---|---|---|---|
| Female | 21 | 23 | 44 |
| Male | 24 | 22 | 46 |
| Region of Enrollment(participants) | 10 mg Olanzapine | Placebo | Total |
|---|---|---|---|
| Japan | 45 | 45 | 90 |
| Diabetes Mellitus Status(participants) | 10 mg Olanzapine | Placebo | Total |
|---|---|---|---|
| Diabetes Mellitus - Yes | 3 | 3 | 6 |
| Diabetes Mellitus - No | 42 | 42 | 84 |
| Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision Diagnosis Status(participants) | 10 mg Olanzapine | Placebo | Total |
|---|---|---|---|
| Catatonic | 0 | 2 | 2 |
| Disorganized | 4 | 3 | 7 |
| Paranoid | 40 | 40 | 80 |
| Undifferentiated | 1 | 0 | 1 |
| Residual | 0 | 0 | 0 |
| Pre-therapy Antipsychotic Usage(participants) | 10 mg Olanzapine | Placebo | Total |
|---|---|---|---|
| Yes (>=1000 milligrams [mg]) | 12 | 11 | 23 |
| Yes (<1000 mg) | 27 | 30 | 57 |
| No | 6 | 4 | 10 |
| Age at Onset(years) | 10 mg Olanzapine | Placebo | Total |
|---|---|---|---|
| Mean | 24.7 ± 9.4 | 27.2 ± 9.3 | 25.9 ± 9.4 |
| Agitation-Calmness Evaluation Scale (ACES) Score(units on a scale) | 10 mg Olanzapine | Placebo | Total |
|---|---|---|---|
| Mean | 1.6 ± 0.5 | 1.6 ± 0.5 | 1.6 ± 0.5 |
1 further baseline measures are reported on the registry.
The record gives a start of Sep 2009, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine